Neuropeptides in the Immune System: Mediators of Stress and Inflammation

  • D. S. Jessop


Neuropeptides and cytokines expressed within the brain and the immune system can act in association with circulating cytokines, catecholamines, and glucocorticoids to form an elegant bidirectional symmetry of brain–immune system communications. Interactions between these compounds are critical for the maintenance of homeostasis during immune system activation and during chronic inflammatory stress. Now that many fundamental principles governing the general anatomy of this network have been established, a major research challenge lies in elucidation of the functional roles of cytokines in the brain and neuropeptides in immune tissues. This chapter will focus on immunoneuropeptides, expression of many of which is altered in autoimmune diseases and also in models of chronic stress associated with inflammation. This has led to the proposition that immunoneuropeptides may be involved in underlying processes in the development of, and the responses to, acute and chronic inflammation. In support of this concept, potential for modulation of inflammation in vivo and in vitro has been demonstrated for many neuropeptides synthesized within immune cells. The purpose of this chapter is to summarize the evidence for involvement of immunoneuropeptides in disease processes and to discuss potential antiinflammatory therapies that may arise from our increased understanding of the roles these compounds play in immune responses.


Opioid Peptide Experimental Allergic Encephalomyelitis Adjuvant Arthritis Human Peripheral Blood Mononuclear Cell Immune Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


adjuvant arthritis


arginine vasopressin


central nervous system


corticotropin-releasing factor


experimental allergic encephalomyelitis










orphanin FQ


peripheral afferent nociceptive


peripheral blood mononuclear cells




rheumatoid arthritis


systemic lupus erythematosus


sympathetic nervous system


substance P


Urocortin 1



We are grateful to The Wellcome Trust for their support for our research into neuroimmunological interactions.


  1. Aird F, Clevenger CV, Prystowsky MB, Redei E. 1993. Corticotropin-releasing factor mRNA in rat thymus and spleen. Proc Natl Acad Sci USA 90: 7104–7108.PubMedCrossRefGoogle Scholar
  2. Arjomand J, Cole S, Evans CJ. 2002. Novel orphanin FQ/nociceptin transcripts are expressed in human immune cells. J Neuroimmunol 130: 100–108.PubMedCrossRefGoogle Scholar
  3. Azuma Y, Wang PL, Shinohara M, Ohura K. 2000. Immunomodulation of the neutrophil respiratory burst by endomorphins 1 and 2. Immunol Lett 75: 55–59.PubMedCrossRefGoogle Scholar
  4. Baigent SM. 2001. Peripheral corticotropin-releasing hormone and urocortin in the control of the immune response. Peptides 22: 809–820.PubMedCrossRefGoogle Scholar
  5. Baker C, Richards LJ, Dayan CM, Jessop DS. 2003. Corticotropin-releasing hormone immunoreactivity in human T and B cells and macrophages: Colocalization with arginine vasopressin. J Neuroendocrinol 15: 1070–1074.PubMedCrossRefGoogle Scholar
  6. Bamberger CM, Wald M, Bamberger AM, Ergun S, Beil FU, et al. 1998. Human lymphocytes produce urocortin, but not corticotropin-releasing hormone. J Clin Endocrinol Metab 83: 708–711.PubMedCrossRefGoogle Scholar
  7. Bhardwaj R, Becher E, Mahnke K, Hartmeyer M, Schwarz T, et al. 1997. Evidence for the differential expression of the functional α-melanocyte-stimulating hormone receptor MC-1 on human monocytes. J Immunol 158: 3378–3384.PubMedGoogle Scholar
  8. Bhardwaj RS, Schwarz A, Becher E, Mahnke K, Aragane Y, et al. 1996. Proopiomelanocortin-derived peptides induce IL-10 production in human monocytes. J Immunol 156: 2517–2521.PubMedGoogle Scholar
  9. Binder W, Mousa SA, Sitte N, Kaiser M, Stein C, et al. 2004. Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue. Eur J Neurosci 20: 92–100.PubMedCrossRefGoogle Scholar
  10. Blalock JE. 1999. Proopiomelanocortin and the immune–neuroendocrine connection. Ann N Y Acad Sci 885: 161–172.PubMedCrossRefGoogle Scholar
  11. Boehme SA, Gaur A, Crowe PD, Liu XJ, Wong T, et al. 1997. Immunosuppressive phenotype of corticotropin-releasing factor transgenic mice is reversed by adrenalectomy. Cell Immunol 176: 103–112.PubMedCrossRefGoogle Scholar
  12. Brouxhon SM, Prasad AV, Joseph SA, Felten DL, Bellinger D. 1998. Localization of corticotropin-releasing factor in primary and secondary lymphoid organs of the rat. Brain Behav Immun 12: 107–122.PubMedCrossRefGoogle Scholar
  13. Buzzetti R, McLoughlin L, Lavender P, Clark A, Rees LH. 1989. Expression of proopiomelanocortin gene and quantification of adrenocorticotropic hormone-like immunoreactivity in human normal peripheral mononuclear cells and lymphoid and myeloid malignancies. J Clin Invest 83: 733–737.PubMedCrossRefGoogle Scholar
  14. Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schafer M, et al. 1997. Immune cell-derived β-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest 100: 142–148.PubMedCrossRefGoogle Scholar
  15. Cabot PJ, Carter L, Schafer M, Stein C. 2001. Methionine-enkephalin- and Dynorphin A-release from immune cells and control of inflammatory pain. Pain 93: 207–212.PubMedCrossRefGoogle Scholar
  16. Carrigan KA, Nelson CJ, Lysle DT. 2000. Endomorphin-1 induces antinociception without immunomodulatory effects in the rat. Psychopharmacology (Berl) 151: 299–305.CrossRefGoogle Scholar
  17. Chancellor-Freeland C, Zhu GF, Kage R, Beller DI, Leeman SE, et al. 1995. Substance P and stress-induced changes in macrophages. Ann N Y Acad Sci 771: 472–484.PubMedCrossRefGoogle Scholar
  18. Chikanza IC, Grossman AB. 1998. Hypothalamic-pituitary-mediated immunomodulation: Arginine vasopressin is a neuroendocrine immune mediator. Br J Rheumatol 37: 131–136.PubMedCrossRefGoogle Scholar
  19. Chowdrey HS, Lightman SL, Harbuz MS, Larsen PJ, Jessop DS. 1994. Contents of corticotropin-releasing hormone and arginine vasopressin immunoreactivity in the spleen and thymus during a chronic inflammatory stress. J Neuroimmunol 53: 17–21.PubMedCrossRefGoogle Scholar
  20. Clarke BL, Bost KL. 1989. Differential expression of functional adrenocorticotropic hormone receptors by subpopulations of lymphocytes. J Immunol 143: 464–469.PubMedGoogle Scholar
  21. Conti F, Pittoni V, Sacerdote P, Priori R, Meroni PL, et al. 1998. Decreased immunoreactive β-endorphin in mononuclear leucocytes from patients with chronic fatigue syndrome. Clin Exp Rheumatol 16: 729–732.PubMedGoogle Scholar
  22. Coventry TL, Jessop DS, Finn DP, Crabb MD, Kinoshita H, et al. 2001. Endomorphins and activation of the hypothalamo-pituitary-adrenal axis. J Endocrinol 169: 185–193.PubMedCrossRefGoogle Scholar
  23. Crofford LJ, Sano H, Karalis K, Friedman TC, Epps HR, et al. 1993. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol 151: 1587–1596.PubMedGoogle Scholar
  24. Crofford LJ, Sano H, Karalis K, Webster E, Goldmuntz E, et al. 1992. Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. J Clin Invest 90: 2555–2564.PubMedCrossRefGoogle Scholar
  25. Ekman R, Servenius B, Castro MG, Lowry PJ, Cederlund AS, et al. 1993. Biosynthesis of corticotropin-releasing hormone in human T lymphocytes. J Neuroimmunol 44: 7–13.PubMedCrossRefGoogle Scholar
  26. Elands J, Van Woudenberg A, Resink A, de Kloet R. 1990. Vasopressin receptor capacity of human blood peripheral mononuclear cells is sex dependent. Brain Behav Immun 4: 30–38.PubMedCrossRefGoogle Scholar
  27. Elenkov IJ, Chrousos GP. 1999. Stress, cytokine patterns, and susceptibility to disease. Bailliere's Best Pract Res Clin Endocrinol Metab 13: 583–595.CrossRefGoogle Scholar
  28. Felten DL, Felten SY, Bellinger SL, Carlson SL, Ackerman KS, et al. 1987. Noradrenergic sympathetic neural interactions with the immune system: Structure and function. Immunol Rev 100: 225–260.PubMedCrossRefGoogle Scholar
  29. Fiset ME, Gilbert C, Poubelle PE, Pouliot M. 2003. Human neutrophils as a source of nociceptin: A novel link between pain and inflammation. Biochemistry 42: 10498–10505.PubMedCrossRefGoogle Scholar
  30. Fuchs BA, Pruett SB. 1993. Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: Involvement of both opiate and glucocorticoid receptors. J Pharmacol Exp Ther 266: 417–423.PubMedGoogle Scholar
  31. Fulford AJ, Harbuz MS, Jessop DS. 2000. Antisense inhibition of proopiomelanocortin and proenkephalin A messenger RNA translation alters rat immune cell function in vitro. J Neuroimmunol 106: 6–13.PubMedCrossRefGoogle Scholar
  32. Gaillard RC, Daneva T, Hadid R, Muller K, Spinedi E. 1998. The hypothalamo-pituitary-adrenal axis of athymic Swiss nude mice. The implications of T lymphocytes in ACTH release from immune cells. Ann N Y Acad Sci 840: 480–490.PubMedCrossRefGoogle Scholar
  33. Galin FS, Le Boeuf RD, Blalock JE. 1991. Corticotropin-releasing factor upregulates expression of two truncated proopiomelanocortin transcripts in murine lymphocytes. J Neuroimmunol 31: 51–58.PubMedCrossRefGoogle Scholar
  34. Getting SJ, Allcock GH, Flower R, Perretti, M. 2001. Natural and synthetic agonists of the melanocortin receptor type 3 possess antiinflammatory properties. J Leukoc Biol 69: 98–104.PubMedGoogle Scholar
  35. Getting SJ, Gibbs L, Clark AJ, Flower RJ, Perretti, M. 1999. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J Immunol 162: 7446–7453.PubMedGoogle Scholar
  36. Groneberg DA, Fischer A. 2001. Endogenous opioids as mediators of asthma. Pulm Pharmacol Ther 14: 383–389.PubMedCrossRefGoogle Scholar
  37. Hallberg M, Nyberg F. 2003. Neuropeptide conversion to bioactive fragments—an important pathway in neuromodulation. Curr Protein Pept Sci 4: 31–44.PubMedCrossRefGoogle Scholar
  38. Harbuz MS, Chover-Gonzalez A, Gibert-Rahola J, Jessop DS. 2002. Protective effect of prior acute immune challenge, but not footshock, on inflammation in the rat. Brain Behav Immun 16: 439–449.PubMedCrossRefGoogle Scholar
  39. Harbuz MS, Chowdrey HS, Lightman SL, Wei ET, Jessop DS. 1996. An investigation into the effects of chronic infusion of corticotropin-releasing factor on hind paw inflammation in adjuvant-induced arthritis. Stress 1: 105–111.CrossRefGoogle Scholar
  40. Hargreaves KM, Costello AH, Joris JL. 1989. Release from inflamed tissue of a substance with properties similar to corticotropin-releasing factor. Neuroendocrinology 49: 476–482.PubMedCrossRefGoogle Scholar
  41. Hashemi FB, Hughes TK, Smith EM. 1998. Human immunodeficiency virus induction of corticotropin in lymphoid cells. J Clin Endocrinol Metab 83: 4373–4381.PubMedCrossRefGoogle Scholar
  42. Hassan AH, Przewlocki R, Herz A, Stein C. 1992. Dynorphin, a preferential ligand for κ-opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the rat. Neurosci Lett 140: 85–88.PubMedCrossRefGoogle Scholar
  43. Heijnen CJ, Zijlstra J, Kavelaars A, Croiset G, Ballieux RE. 1987. Modulation of the immune response by POMC-derived peptides. I. Influence on proliferation of human lymphocytes. Brain Behav Immun 1: 284–291.PubMedCrossRefGoogle Scholar
  44. Hook S, Camberis M, Prout M, Le Gros G. 2003. Absence of preproenkephalin increases the threshold for T cell activation. J Neuroimmunol 140: 61–68.PubMedCrossRefGoogle Scholar
  45. Ientile R, Ginoprelli T, Cannavo G, Picerno I, Piedimonte G. 1997. Effect of β-endorphin on cell growth and cell death in human peripheral blood lymphocytes. J Neuroimmunol 80: 87–92.PubMedCrossRefGoogle Scholar
  46. Jessop DS. 1998. Neuropeptides: Modulators of the immune system. Curr Opin Endocrinol Diabetes 5: 52–58.CrossRefGoogle Scholar
  47. Jessop DS. 2001. Neuropeptides in the immune system: Functional roles in health and disease. Frontiers of Hormone Research, Vol. 29. Gaillard R, editor. Basel: S. Karger AG; pp. 50–68.Google Scholar
  48. Jessop DS. 2002. Neuropeptides: Modulators of immune responses in health and disease. Int Rev Neurobiol 52: 67–91.PubMedCrossRefGoogle Scholar
  49. Jessop DS. 2006. Endomorphins as agents for the treatment of chronic inflammatory disease. Bio Drugs 20:161–166.Google Scholar
  50. Jessop DS, Chowdrey HS, Lightman SL, Larsen PJ. 1995b. Vasopressin is located within lymphocytes in the rat spleen. J Neuroimmunol 56: 219–223.CrossRefGoogle Scholar
  51. Jessop DS, Douthwaite JD, Conde GL, Lightman SL, Dayan CM, et al. 1997b. Effects of acute stress or centrally injected interleukin-1β on neuropeptide expression in the immune system. Stress 2: 133–144.CrossRefGoogle Scholar
  52. Jessop DS, Harbuz MS, Lightman SL. 2001. CRH in chronic inflammatory stress. Peptides 22: 803–807.PubMedCrossRefGoogle Scholar
  53. Jessop DS, Harbuz MS, Snelson CL, Dayan CM, Lightman SL. 1997a. An antisense oligodeoxynucleotide complementary to corticotropin-releasing hormone mRNA inhibits rat splenocyte proliferation in vitro. J Neuroimmunol 75: 135–140.CrossRefGoogle Scholar
  54. Jessop DS, Lightman SL, Chowdrey HS. 1994. Effects of a chronic inflammatory stress on levels of proopiomelanocortin-derived peptides in the rat spleen and thymus. J Neuroimmunol 49: 197–203.PubMedCrossRefGoogle Scholar
  55. Jessop DS, Major GN, Coventry TL, Kaye SJ, Fulford AJ, et al. 2000. Opioid peptides endomorphin-1 and endomorphin-2 are present in mammalian immune tissues. J Neuroimmunol 106: 53–59.PubMedCrossRefGoogle Scholar
  56. Jessop DS, Patience RL, Cunnah D, Rees LH. 1987. The use of reversed-phase high-performance liquid chromatography to detect proteolytic activity from human pancreas in a radioimmunoassay for corticotropin-releasing factor. J Endocrinol 114: 147–151.PubMedCrossRefGoogle Scholar
  57. Jessop DS, Renshaw D, Lightman SL, Harbuz MS. 1995a. Changes in ACTH and β-endorphin immunoreactivity in immune tissues during a chronic inflammatory stress are not correlated with changes in corticotropin-releasing hormone and arginine vasopressin. J Neuroimmunol 60: 29–35.CrossRefGoogle Scholar
  58. Jessop DS, Richards LJ, Harbuz MS. 2002. Opioid peptides endomorphin (EM)-1 and EM-2 in the immune system in a rodent model of inflammation. Ann N Y Acad Sci 966: 456–463.PubMedCrossRefGoogle Scholar
  59. Jessop DS, Richards LJ, Harbuz MS. 2004. Effects of stress on inflammatory autoimmune disease: Destructive or protective? Stress 7: 261–266.PubMedCrossRefGoogle Scholar
  60. Johnson EW, Hughes TK, Jr, Smith EM. 2001. ACTH receptor distribution and modulation among murine mononuclear leukocyte populations. J Biol Regul Homeost Agents 15: 156–162.PubMedGoogle Scholar
  61. Jordan BA, Devi LA. 1999. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399: 697–700.PubMedCrossRefGoogle Scholar
  62. Kageyama K, Bradbury MJ, Zhao L, Blount AL, Vale WW. 1999. Urocortin messenger ribonucleic acid: Tissue distribution in the rat and regulation in thymus by lipopolysaccharide and glucocorticoids. Endocrinology 140: 5651–5658.PubMedCrossRefGoogle Scholar
  63. Kaiser MJ, Tiegs G, Neuhuber WL. 2003. Close apposition of dynorphin-positive nerve fibers to lymphocytes in the liver suggests opioidergic neuroimmunomodulation. Histochem Cell Biol 120: 213–221.PubMedCrossRefGoogle Scholar
  64. Kamphuis S, Eriksson F, Kavelaars A, Zijlstra J, van de Pol M, et al. 1998. Role of endogenous proenkephalin A-derived peptides in human T cell proliferation and monocyte IL-6 production. J Neuroimmunol 84: 53–60.PubMedCrossRefGoogle Scholar
  65. Kamphuis S, Kavelaars A, Brooimans R, Kuis W, Zegers BJM, et al. 1997. T H2 cytokines induce preproenkephalin mRNA expression and proenkephalin A in human peripheral blood mononuclear cells. J Neuroimmunol 79: 91–99.PubMedCrossRefGoogle Scholar
  66. Karalis K, Muglia LJ, Bae D, Hilderbrand H, Majzoud JA. 1997. CRH and the immune system. J Neuroimmunol 72: 131–136.PubMedCrossRefGoogle Scholar
  67. Karalis K, Sano H, Redwine J, Listwak J, Wilder R, et al. 1991. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254: 421–423.PubMedCrossRefGoogle Scholar
  68. Kavelaars A, Ballieux RE, Heijnen CJ. 1989. The role of IL-1 in the corticotropin-releasing factor and arginine-vasopressin-induced secretion of immunoreactive β-endorphin by human peripheral blood mononuclear cells. J Immunol 142: 2338–2342.PubMedGoogle Scholar
  69. Kavelaars A, Ballieux RE, Heijnen CJ. 1990. In vitro β-adrenergic stimulation of lymphocytes induces the release of immunoreactive β-endorphin. Endocrinology 126: 3028–3032.PubMedCrossRefGoogle Scholar
  70. Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska K, et al. 2004. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 145: 43–48.PubMedCrossRefGoogle Scholar
  71. Khalil Z, Sanderson K, Modig M, Nyberg F. 1999. Modulation of peripheral inflammation by locally administered endomorphin-1. Inflamm Res 48: 550–556.PubMedCrossRefGoogle Scholar
  72. Kohno M, Kawahito Y, Tsubouchi Y, Hashiramoto A, Yamada R, et al. 2001. Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: Relation to inflammatory activity. J Clin Endocrinol Metab 86: 4344–4352.PubMedCrossRefGoogle Scholar
  73. Kong LY, McMillian MK, Hudson PM, Jin L, Hong JS. 1997. Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. J Pharmacol Exp Ther 280: 61–66.PubMedGoogle Scholar
  74. Kraus J, Borner C, Giannini E, Hickfang K, Braun H, et al. 2001. Regulation of μ-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor-binding site. J Biol Chem 276: 43901–43908.PubMedCrossRefGoogle Scholar
  75. Kusnecov AW, Husband AJ, King MG, Smith R. 1989. Modulation of mitogen-induced spleen cell proliferation and the antibody-forming cell response by β-endorphin in vivo. Peptides 10: 473–479.PubMedCrossRefGoogle Scholar
  76. Linner KM, Quist HE, Sharp BM. 1995. Met-enkephalin-containing peptides encoded by proenkephalin A mRNA expressed in activated murine thymocytes inhibit thymocyte proliferation. J Immunol 154: 5049–5060.PubMedGoogle Scholar
  77. Lipton JM, Catania A. 1998. Mechanisms of antiinflammatory action of the neuroimmunomodulatory peptide α-MSH. Ann N Y Acad Sci 840: 373–380.PubMedCrossRefGoogle Scholar
  78. Lolait S, Clements JA, Markwick A, Cheng C, McNulty M, et al. 1986. Proopiomelanocortin messenger ribonucleic acid and posttranslational processing of β-endorphin in spleen macrophages. J Clin Invest 77: 1776–1779.PubMedCrossRefGoogle Scholar
  79. Lyons PD, Blalock JE. 1995. The kinetics of ACTH expression in rat leukocyte subpopulations. J Neuroimmunol 63: 103–112.PubMedCrossRefGoogle Scholar
  80. Lyons PD, Blalock JE. 1997. Proopiomelanocortin gene expression and protein processing in rat mononuclear leukocytes. J Neuroimmunol 78: 47–56.PubMedCrossRefGoogle Scholar
  81. McCain HW, Lamster IB, Bozzone JM, Grbic JT. 1982. β-Endorphin modulates human immune activity via nonopiate receptor mechanisms. Life Sci 31: 1619–1624.PubMedCrossRefGoogle Scholar
  82. McDougall JJ, Baker CL, Hermann PM. 2004. Attenuation of knee joint inflammation by peripherally administered endomorphin-1. J Mol Neurosci 22: 125–137.PubMedCrossRefGoogle Scholar
  83. McEvoy AN, Bresnihan B, Fitz Gerald O, Murphy EP. 2001. Corticotropin-releasing hormone signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1 α-corticotropin-releasing hormone receptor. Arthritis Rheum 44: 1761–1767.PubMedCrossRefGoogle Scholar
  84. Machelska H, Cabot PJ, Mousa SA, Zhang Q, Stein C. 1998. Pain control in inflammation governed by selectins. Nature Med 4: 1425–1428.PubMedCrossRefGoogle Scholar
  85. Machelska H, Pfluger M, Weber W, Piranvisseh-Volk M, Daubert JD, et al. 1999. Peripheral effects of the κ-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther 290: 354–361.PubMedGoogle Scholar
  86. Madden JJ, Whaley WL, Ketelsen D, Donahoe RM. 2001. The morphine-binding site on human activated T cells is not related to the μ-opioid receptor. Drug Alcohol Depend 62: 131–139.PubMedCrossRefGoogle Scholar
  87. Martens H, Goxe B, Geenen V. 1996. The thymic repertoire of neuroendocrine self-antigens: Physiological implications in T cell life and death. Immunol Today 17: 312–317.PubMedCrossRefGoogle Scholar
  88. Menzebach A, Hirsch J, Hempelmann G, Welters ID. 2003. Effects of endogenous and synthetic opioid peptides on neutrophil function in vitro. Br J Anaesth 91: 546–550.PubMedCrossRefGoogle Scholar
  89. Mollereau C, and Mouledous L. 2000. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 21: 907–917.PubMedCrossRefGoogle Scholar
  90. Mousa SA, Schafer M, Mitchell WM, Hassan AH, Stein C. 1996. Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation. Eur J Pharmacol 311: 221–231.PubMedCrossRefGoogle Scholar
  91. Mousa SA, Shakibaei M, Sitte N, Schafer M, Stein C. 2004. Subcellular pathways of β-endorphin synthesis, processing, and release from immunocytes in inflammatory pain. Endocrinology 145: 1331–1341.PubMedCrossRefGoogle Scholar
  92. Murphy EP, McEvoy A, Conneely OM, Bresnihan B, Fitz Gerald O. 2001. Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum 44: 782–793.PubMedCrossRefGoogle Scholar
  93. Ni X, Lin BC, Song CY, Wang CH. 1999. Dynorphin A enhances mitogen-induced proliferative response and interleukin-2 production of rat splenocytes. Neuropeptides 33: 137–143.PubMedCrossRefGoogle Scholar
  94. Nishioka T, Kurokawa H, Takao T, Kumon Y, Nishiya K, et al. 1996. Differential changes of corticotropin releasing hormone (CRH) concentrations in plasma and synovial fluids of patients with rheumatoid arthritis (RA). Endocr J 43: 241–247.PubMedCrossRefGoogle Scholar
  95. Ohsawa M, Mizoguchi H, Narita M, Nagase H, Kampine JP, et al. 2001. Differential antinociception induced by spinally administered endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 298: 592–597.PubMedGoogle Scholar
  96. Owen DL, Morley JS, Ensor DM, Miles JB. 1998. The C-terminal tetrapeptide of β-endorphin (MPF) enhances lymphocyte proliferative responses. Neuropeptides 32: 131–139.PubMedCrossRefGoogle Scholar
  97. Pampusch MS, Serie JR, Osinski MA, Seybold VS, Murtaugh MP, et al. 2000. Expression of nociceptin/OFQ receptor and prepronociceptin/OFQ in lymphoid tissues. Peptides 21: 1865–1870.PubMedCrossRefGoogle Scholar
  98. Panerai AE, Sacerdote P. 1997. β-Endorphin in the immune system: A role at last? Immunol Today 18: 317–319.PubMedCrossRefGoogle Scholar
  99. Panerai AE, Sacerdote P, Bianchi M, Manfredi B. 1997. Intermittent but not continuous inescapable footshock stress and intracerebroventricular interleukin-1 similarly affect immune responses and immunocyte β-endorphin concentrations in the rat. Int J Clin Pharmacol Res 17: 115–126.PubMedGoogle Scholar
  100. Park JH, Lee YJ, Na SY, Kim KL. 2000. Genomic organization and tissue-specific expression of rat urocortin. Neurosci Lett 292: 45–48.PubMedCrossRefGoogle Scholar
  101. Pasnik J, Tchorzewski H, Baj Z, Luciak M, Tchorzewski M 1999. Priming effect of met-enkephalin and β-endorphin on chemiluminescence, chemotaxis, and CD11b molecule expression on human neutrophils in vitro. Immunol Lett 67: 77–83.PubMedCrossRefGoogle Scholar
  102. Patchev, VK, Mastorakos G, Brady LS, Redwine J, Wilder RL, et al. 1993. Increased arginine vasopressin secretion may participate in the enhanced susceptibility of Lewis rats to inflammatory disease. Neuroendocrinology 58: 106–110.PubMedCrossRefGoogle Scholar
  103. Peluso J, Gaveriaux-Ruff C, Matthes HW, Filliol D, Kieffer BL. 2001. Orphanin FQ/nociceptin binds to functionally coupled ORL1 receptors on human immune cell lines and alters peripheral blood mononuclear cell proliferation. Brain Res Bull 54: 655–660.PubMedCrossRefGoogle Scholar
  104. Peluso J, La Forge KS, Matthes HW, Kreek MJ, Kieffer BL, et al. 1998. Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol 81: 184–192.PubMedCrossRefGoogle Scholar
  105. Poliak S, Mor F, Conlon P, Wong T, Ling N, et al. 1997. Stress and autoimmunity: The neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. J Immunol 158: 5751–5756.PubMedGoogle Scholar
  106. Przewlocki R, Hassan AHS, Lason W, Epplen C, Herz A, et al. 1992. Gene expression and localization of opioid peptides in immune cells of inflamed tissue: Functional role in antinociception. Neuroscience 48: 491–500.PubMedCrossRefGoogle Scholar
  107. Raap T, Justen HP, Miller LE, Cutolo M, Scholmerich J, et al. 2000. Neurotransmitter modulation of interleukin-6 (IL-6) and IL-8 secretion of synovial fibroblasts in patients with rheumatoid arthritis compared to osteoarthritis. J Rheumatol 27: 2558–2565.PubMedGoogle Scholar
  108. Radulovic M, Dautzenberg FM, Sydow S, Radulovic J, Spiess J. 1999. Corticotropin-releasing factor receptor 1 in mouse spleen: Expression after immune stimulation and identification of receptor-bearing cells. J Immunol 162: 3013–3021.PubMedGoogle Scholar
  109. Reder AT. 1992. Regulation of production of adrenocorticotropin-like proteins in human mononuclear cells. Immunology 77: 436–442.PubMedGoogle Scholar
  110. Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M, et al. 2001. Opioid peptide-expressing leukocytes: Identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology 95: 500–508.PubMedCrossRefGoogle Scholar
  111. Roy S, Ge BL, Ramakrishnan S, Lee NM, Loh HH. 1991. [ 3H]morphine binding is enhanced by IL-1-stimulated thymocyte proliferation. FEBS Lett 287: 93–96.PubMedCrossRefGoogle Scholar
  112. Sacerdote P, di San Secondo VE, Sirchia G, Manfredi B, Panerai AE. 1998. Endogenous opioids modulate allograft rejection time in mice: Possible relation with T H1/T H2 cytokines. Clin Exp Immunol 113: 465–469.PubMedCrossRefGoogle Scholar
  113. Sacerdote P, Gaspani L, Panerai AE. 2000. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann N Y Acad Sci 917: 755–763.PubMedCrossRefGoogle Scholar
  114. Sakurada S, Hayashi T, Yuhki M, Orito T, Zadina JE, et al. 2001. Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse. Eur J Pharmacol 427: 203–210.PubMedCrossRefGoogle Scholar
  115. Sashinami H, Kageya K, Suda T, Nakane A. 2005. Urocortin 2 suppresses host resistance to Listeria monocytogenes infection via upregulation of IL-10. Endocrinology 146: 5003–5111.PubMedCrossRefGoogle Scholar
  116. Sawchenko PE, Imaki T, and Vale W. 1992. Colocalization of neuroactive substances in the endocrine hypothalamus. Ciba Found Symp 168: 16–42.PubMedGoogle Scholar
  117. Schafer M, Mousa SA, Stein C. 1997. Corticotropin-releasing factor in antinociception and inflammation. Eur J Pharmacol 323: 1–10.PubMedCrossRefGoogle Scholar
  118. Seale JV, Jessop DS, Harbuz MS. 2004. Immunohistochemical staining of endomorphin 1 and 2 in the immune cells of the spleen. Peptides 25: 91–94.PubMedCrossRefGoogle Scholar
  119. Serhan CN, Fierro IM, Chiang N, Pouliot M. 2001. Nociceptin stimulates neutrophil chemotaxis and recruitment: Inhibition by aspirin-triggered-15-epi-lipoxin A 4. J Immunol 166: 3650–3654.PubMedGoogle Scholar
  120. Shahabi NA, Linner KM, Sharp BM. 1990. Murine splenocytes express a naloxone-insensitive binding site for β-endorphin. Endocrinology 126: 1442–1448.PubMedCrossRefGoogle Scholar
  121. Sharp BM. 2003. Opioid receptor expression and intracellular signaling by cells involved in host defense and immunity. Adv Exp Med Biol 521: 98–105.PubMedGoogle Scholar
  122. Skofitsch G, Hamill GS, Jacobowitz DM. 1984. Capsaicin depletes corticotropin-releasing factor-like immunoreactive neurons in the rat spinal cord and medulla oblongata. Neuroendocrinology 38: 514–517.PubMedCrossRefGoogle Scholar
  123. Singh LK, Boucher W, Pang X, Letourneau R, Seretakis D, et al. 1999. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. J Pharmacol Exp Ther 288: 1349–1356.PubMedGoogle Scholar
  124. Singh V. 1989. Stimulatory effect of corticotropin-releasing neurohormone on human lymphocyte proliferation and interleukin-2 receptor expression. J Neuroimmunol 23: 256–262.CrossRefGoogle Scholar
  125. Singh V, Leu C. 1990. Enhancing effect of corticotropin-releasing neurohormone on the production of interleukin-1 and interleukin-2. Neurosci Lett 120: 151–154.PubMedCrossRefGoogle Scholar
  126. Smith EM, Brosnan P, Meyer WJ, Blalock JE. 1987. An ACTH receptor on human mononuclear leukocytes. New Eng J Med 317: 1266–1269.PubMedCrossRefGoogle Scholar
  127. Smith EM, Morrill AC, Meyer WJ, Blalock JE. 1986. Corticotropin-releasing factor induction of leukocyte-derived immunoreactive ACTH and endorphins. Nature 321: 881PubMedCrossRefGoogle Scholar
  128. Solomon GF. 1997. Clinical and social implications of stress-induced neuroendocrine–immune interactions. Stress, stress hormones, and the immune system. Buckingham JC, Gillies GE, Cowell AM, editors. Chichester: John Wiley & Sons; pp. 225–239.Google Scholar
  129. Star RA, Rajora N, Huang J, Stock RC, Catania A, et al. 1995. Evidence of autocrine modulation of macrophage nitric oxide synthase by α-melanocyte-stimulating hormone. Proc Natl Acad Sci USA 92: 8016–8020.PubMedCrossRefGoogle Scholar
  130. Stein C, Hassan AHS, Lehrberger K, Giefing J, Yassouridis A. 1993. Local analgesic effect of endogenous opioid peptides. Lancet 342: 321–322.PubMedCrossRefGoogle Scholar
  131. Stenzel-Poore MP, Duncan JE, Rittenberg MB, Bakke AC, Heinrichs SC. 1996. CRH overproduction in transgenic mice. Ann N Y Acad Sci 780: 36–48.PubMedCrossRefGoogle Scholar
  132. Stephanou A, Jessop DS, Knight RA, Lightman SL. 1990. Corticotropin-releasing factor-like immunoreactivity and mRNA in human leucocytes. Brain Behav Immun 4: 67–73.PubMedCrossRefGoogle Scholar
  133. Straub RH, Dorner M, Riedel J, Kubitza M, Van Rooijen N, et al. 1998. Tonic neurogenic inhibition of interleukin-6 secretion from murine spleen caused by opioidergic transmission. Am J Physiol 274: R997–1003.PubMedGoogle Scholar
  134. Swinny JD, Metzger F, Ijkema-Paassen J, Gounko NV, Gramsbergen A, et al. 2004. Corticotropin-releasing factor and urocortin differentially modulate rat Purkinje cell dendritic outgrowth and differentiation in vitro. Eur J Neurosci 19: 1749–1758.PubMedCrossRefGoogle Scholar
  135. Takeba Y, Suzuki N, Kaneko A, Asai T, Sakane T. 2001. Endorphin and enkephalin ameliorate excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 28: 2176–2183.PubMedGoogle Scholar
  136. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, et al. 1998. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 139: 403–413.PubMedCrossRefGoogle Scholar
  137. Thomas HA, Ling N, Wei ET. 1993. CRF and related peptides as antiinflammatory agonists. Ann NY Acad Sci 697: 219–228.PubMedCrossRefGoogle Scholar
  138. Turner-Cobb JM. 2002. Psychological and neuroendocrine correlates of disease progression. Int Rev Neurobiol 52: 353–381.PubMedCrossRefGoogle Scholar
  139. Udelsman R, Harwood JP, Millan MA, Chrousos GP, Goldstein DS, et al. 1986. Functional corticotropin-releasing factor receptors in the primate peripheral sympathetic nervous system. Nature 319: 147–150.PubMedCrossRefGoogle Scholar
  140. Uzuki M, Sasano H, Muramatsu Y, Totsune K, Takahashi K, et al. 2001. Urocortin in the synovial tissue of patients with rheumatoid arthritis. Clin Sci (Lond) 100: 577–589.CrossRefGoogle Scholar
  141. Vanneste Y, Thome AN, Vandermissen E, Charlet C, Franchimont D, et al. 1997. Identification of neurotensin-related peptides in human thymic epithelial cell membranes with major histocompatibility complex class 1 molecules. J Neuroimmunol 76: 161–166.PubMedCrossRefGoogle Scholar
  142. Venihaki M, Dikkes P, Carrigan A, Karalis KP. 2001. Corticotropin-releasing hormone regulates IL-6 expression during inflammation. J Clin Invest 108: 1159–1166.PubMedGoogle Scholar
  143. Waits PS, Purcell WM, Fulford AJ, McLeod JD. 2004. Nociceptin/orphanin FQ modulates human T cell function in vitro. J Neuroimmunol 149: 110–120.PubMedCrossRefGoogle Scholar
  144. Whitnall MH, Mezey E, Gainer H. 1985. Colocalization of corticotropin-releasing factor and vasopressin in median eminence neurosecretory vesicles. Nature 317: 248–250.PubMedCrossRefGoogle Scholar
  145. Williamson SA, Knight RA, Lightman SL, Hobbs JR. 1988. Effects of β-endorphin on specific immune responses in man. Immunology 65: 47–51.PubMedGoogle Scholar
  146. Woods RJ, David J, Baigent S, Gibbins J, Lowry PJ. 1996. Elevated levels of corticotropin-releasing factor-binding protein in the blood of patients suffering from arthritis and septicemia and the presence of novel ligands in synovial fluid. Br J Rheumatol 35: 120–124.PubMedCrossRefGoogle Scholar
  147. Yin D, Mufson A, Wang R, Shi Y. 1999. Fas-mediated cell death promoted by opioids. Nature 397: 218.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • D. S. Jessop

There are no affiliations available

Personalised recommendations